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Abstract
Background—Evidence suggests the incidence of oral tongue squamous cell carcinoma is 
increasing in young patients, many who have no history of tobacco use.
Methods—We clinically reviewed 89 oral tongue cancer patients. Exomic sequencing of tumor 
DNA from 6 non-smokers was performed and compared to previously sequenced cases. RNA 
from 20 tumors was evaluated by massively parallel sequencing to search for potentially 
oncogenic viruses.
Results—Non-smokers (53 of 89) were younger than smokers (36 of 89) mean 50.4 vs. 61.9 
years, P<0.001), and appeared more likely to be female, (58.5% vs. 38.9%, P=0.069). Non-
smokers had fewer TP53 mutations (P=0.02) than smokers. No tumor-associated viruses were 
detected.
Conclusions—The young age of non-smoker oral tongue cancer patients, and fewer TP53 
mutations suggest a viral role in this disease. Our efforts to identify such a virus were 
unsuccessful. Further studies are warranted to elucidate the drivers of carcinogenesis in these 
patients.
Keywords
Head and neck cancer; oral tongue; squamous cell carcinoma; next-generation sequencing; 
nonsmokers
Introduction
Historically, tobacco consumption has been the most significant risk factor for developing 
head and neck squamous cell carcinoma (HNSCC), while a multiplicative increase in cancer 
risk has been shown with concomitant alcohol abuse 1–3. An overall decline in tobacco 
consumption has led to a decreasing incidence of head and neck squamous cell carcinoma. 
The most notable exception is the increasing incidence of oropharyngeal SCC, attributable 
to infection with Human Papilloma Virus (HPV). More recently, an increasing incidence of 
oral tongue cancers in young patients has also been described 4. This subsite is distinct from 
the oropharynx, and a robust, multi-institutional study confirmed that HPV does not play a 
significant role in the etiology of oral tongue SCCs 5. Epidemiologically it appears that oral 
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tongue SCC is most commonly arising in young, white, female patients 4. In fact, in young 
HNSCC patients without a history of tobacco use, or association with HPV, the oral tongue 
appears to be the most common subsite of origin 6.
This important clinical entity has ignited interest in identifying undiscovered environmental 
and biological risk factors beyond tobacco use. We, therefore, were interested in comparing 
clinico-demographic differences between non-smokers and smokers with oral tongue cancer 
and sought to identify differences in the genomic and metagenomic profiles between these 
two subgroups of oral tongue cancer patients.
Materials and Methods
Patients
After gaining approval of the Institutional Review Board (IRB) at the Johns Hopkins 
Medical Institutions, a retrospective review of patients treated for oral tongue SCC from 
1984 to 2011, at Johns Hopkins Hospital (JHH) was performed. All patients were surgically 
treated and had no prior history of radiation or chemotherapy. All patients provided written 
informed consent for obtaining medical information and tissue for research purposes.
Clinical Data
Clinical and demographic data including age, gender, race, tobacco and alcohol use were 
abstracted from electronic medical records. Patients with no tobacco smoking or chewing 
history were classified as never-smokers. Subjects with any history of tobacco consumption 
were categorized as smokers. Clinicopathologic variables of interest included tumor 
histologic grade7, TNM classification8, treatment regimen, and disease status (no recurrence, 
local, regional, or distant recurrence).
Preparation of clinical samples
Fresh-frozen surgically resected carcinoma and matched blood were obtained from patients 
under IRB-approved protocols from Johns Hopkins University (JHH), University of 
California, San Francisco (UCSF) and Ohio State University (OSU). All samples were snap 
frozen at the time of surgery and stored at −80 until the time of processing. Six tumors were 
selected from JHU for exome sequencing based on lack of tobacco use and stringent quality 
assessment of normal and tumor DNA. In our tumor bank, the availability of oral tongue 
tumors from non-smokers with high tumor cellularity and sufficient high quality tumor and 
matched normal DNA is limited precluding a larger cohort. Ten samples from UCSF (8 
tumors, 1 healthy control and 1 HPV positive oropharyngeal tumor) and seven tumor 
samples from OSU, in addition to five of the six samples from JHU, were selected for 
transcriptomic analysis. Prior to analysis, the diagnosis of each specimen underwent central 
pathological review. Tumor tissue was analyzed by frozen section to assess neoplastic 
cellularity. Tumors were macrodissected (JHU and OSU) to remove residual normal tissue 
and enhance neoplastic cellularity, as confirmed by serial frozen sections. An estimated 
average of 60% neoplastic cellularity was obtained.
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Preparation of genomic DNA and cDNA libraries
Genomic DNA and cDNA libraries were prepared following Illumina’s (Illumina, San 
Diego, CA) suggested protocol with the following modifications. (1) gDNA from tumor, 
gDNA from normal cells, or cDNA in 100 microliters (μl) of buffer was fragmented in a 
Covaris sonicator (Covaris, Woburn, MA) to a size of 100–500 bp. DNA was purified with a 
PCR purification kit (Cat # 28104, Qiagen, Valencia, CA) and eluted in elution buffer 
included in the kit. (2) Purified, fragmented DNA was mixed with 40 μl of H2O, 10 μl of 10 
× T4 ligase buffer with 10 mM ATP, 4 μl of 10 mM dNTP, 5 μl of T4 DNA polymerase, 1 
μl of Klenow Polymerase, and 5 μl of T4 polynucleotide kinase. All reagents used for this 
step and those described below were from New England Biolabs (NEB, Ipswich, MA) 
unless otherwise specified. The 100 μl end-repair mixture was incubated at 20°C for 30 min, 
purified by a PCR purification kit (Cat # 28104, Qiagen) and eluted with 32 μl of elution 
buffer (EB). (3) To A-tail, all 32 μl of end-repaired DNA was mixed with 5 μl of 10 × Buffer 
(NEB buffer 2), 10 μl of 1 mM dATP and 3 μl of Klenow (exo-). The 50 μl mixture was 
incubated at 37°C for 30 min before DNA was purified with a MinElute PCR purification 
kit (Cat # 28004, Qiagen). Purified DNA was eluted with 12.5 μl of 70°C EB and obtained 
with 10 μl of EB. (4) For adaptor ligation, 10 μl of A-tailed DNA was mixed with 10 μl of 
PE-adaptor (Illumina), 25 μl of 2x Rapid ligase buffer and 5 μl of Rapid Ligase. The ligation 
mixture was incubated at room temperature (RT) or 20°C for 15 min. (5) To purify adaptor- 
ligated DNA, 50 μl of ligation mixture from step (4) was mixed with 200 μl of NT buffer 
from NucleoSpin Extract II kit (cat# 636972, Clontech, Mountain View, CA) and loaded 
into a NucleoSpin column. The column was centrifuged at 14,000 g in a desktop centrifuge 
for 1 min, washed once with 600 μl of wash buffer (NT3 from Clontech), and centrifuged 
again for 2 min to dry completely. DNA was eluted in 50 μl elution buffer included in the 
kit. (6) To obtain an amplified library, ten PCRs of 25 μl each were set up, each including 
13.25 μl of H2O, 5 μl of 5 × Phusion HF buffer, 0.5 μl of a dNTP mix containing 10 mM of 
each dNTP, 0.5 μl of Illumina PE primer #1, 0.5 μl of Illumina PE primer #2, 0.25 μl of 
Hotstart Phusion polymerase, and 5 μl of the DNA from step (5). The PCR program used 
was: 98°C 1 minute; 6 cycles of 98°C for 20 seconds, 65°C for 30 seconds, 72 °C for 30 
seconds; and 72 °C for 5 min. To purify the PCR product, 250 μl PCR mixture (from the ten 
PCR reactions) was mixed with 500 μl NT buffer from a NucleoSpin Extract II kit and 
purified as described in step (5). Library DNA was eluted with 70°C elution buffer and the 
DNA concentration was estimated by absorption at 260 nm.
Exome DNA Capture
Human exome capture was performed following a protocol from Agilent’s SureSelect 
Paired-End Version 2.0 Human Exome Kit (Agilent, Santa Clara, CA) with the following 
modifications. (1) A hybridization mixture was prepared containing 25 μl of SureSelect Hyb 
# 1, 1 μl of SureSelect Hyb # 2, 10 μl of SureSelect Hyb # 3, and 13 μl of SureSelect Hyb # 
4. (2) 3.4 μl (0.5 μg) of the PE-library DNA described above, 2.5 μl of SureSelect Block #1, 
2.5 μl of SureSelect Block #2 and 0.6 μl of Block #3; was loaded into one well in a 384-well 
Diamond PCR plate (cat# AB-1111, Thermo-Scientific, Lafayette, CO), sealed with 
microAmp clear adhesive film (cat# 4306311; ABI, Carlsbad, CA) and placed in GeneAmp 
PCR system 9700 thermocycler (Life Sciences Inc., Carlsbad CA) for 5 minutes at 95°C, 
Li et al. Page 4






















then held at 65°C (with the heated lid on). (3) 25–30 μl of hybridization buffer from step (1) 
was heated for at least 5 minutes at 65°C in another sealed plate with heated lid on. (4) 5 μl 
of SureSelect Oligo Capture Library, 1 μl of nuclease-free water, and 1 μl of diluted RNase 
Block (prepared by diluting RNase Block 1: 1 with nuclease-free water) were mixed and 
heated at 65°C for 2 minutes in another sealed 384-well plate. (5) While keeping all 
reactions at 65°C, 13 μl of Hybridization Buffer from Step (3) was added to the 7 μl of the 
SureSelect Capture Library Mix from Step (4) and then the entire contents (9 μl) of the 
library from Step (2). The mixture was slowly pipetted up and down 8 to 10 times. (6) The 
384-well plate was sealed tightly and the hybridization mixture was incubated for 24 hours 
at 65°C with a heated lid.
After hybridization, five steps were performed to recover and amplify the captured DNA 
library: (1) Magnetic beads for recovering captured DNA: 50 μl of Dynal MyOne 
Streptavidin C1 magnetic beads (Cat # 650.02, Invitrogen Dynal, AS Oslo, Norway) was 
placed in a 1.5 ml microfuge tube and vigorously resuspended on a vortex mixer. Beads 
were washed three times by adding 200 μl of SureSelect Binding buffer, mixing on a vortex 
for five seconds and then removing the supernatant after placing the tubes in a Dynal 
magnetic separator. After the third wash, beads were resuspended in 200 μl of SureSelect 
Binding buffer. (2) To bind captured DNA, the entire hybridization mixture described above 
(29 μl) was transferred directly from the thermocycler to the bead solution and mixed gently; 
the hybridization mix/bead solution was incubated in an Eppendorf thermomixer at 850 rpm 
for 30 minutes at room temperature. (3) To wash the beads, the supernatant was removed 
from beads after applying a Dynal magnetic separator and the beads were resuspended in 
500 μl SureSelect Wash Buffer #1 by mixing on vortex mixer for 5 seconds, then incubated 
for 15 minutes at room temperature. Wash Buffer #1 was then removed from beads after 
magnetic separation. The beads were further washed three times, each with 500 μl pre-
warmed SureSelect Wash Buffer #2 after incubation at 65°C for 10 minutes. After the final 
wash, SureSelect Wash Buffer #2 was completely removed. (4) To elute captured DNA, the 
beads were suspended in 50 μl SureSelect Elution Buffer, vortex-mixed and incubated for 10 
minutes at room temperature. The supernatant was removed after magnetic separation, 
collected in a new 1.5 ml microcentrifuge tube, and mixed with 50 μl of SureSelect 
Neutralization Buffer. DNA was purified with a Qiagen MinElute column and eluted in 17 
μl of 70°C EB to obtain 15 μl of captured DNA library. (5) The captured DNA library was 
amplified in the following way: 15 PCR reactions each containing 9.5 μl of H2O, 3 μl of 5 × 
Phusion HF buffer, 0.3 μl of 10 mM dNTP, 0.75 μl of DMSO, 0.15 μl of Illumina PE primer 
#1, 0.15μl of Illumina PE primer #2, 0.15 μl of Hotstart Phusion polymerase, and 1 μl of 
captured exome library were set up. The PCR program used was: 98°C for 30 seconds; 14 
cycles of 98°C for 10 seconds, 65°C for 30 seconds, 72°C for 30 seconds; and 72°C for 5 
min. To purify PCR products, 225μl PCR mixture (from 15 PCR reactions) was mixed with 
450 μl NT buffer from NucleoSpin Extract II kit and purified as described above. The final 
library DNA was eluted with 30 μl of 70°C elution buffer and DNA concentration was 
estimated by OD260 measurement.
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Somatic Mutation Identification by Massively Parallel Sequencing
Captured DNA libraries were sequenced with the Illumina GAIIx Genome Analyzer, 
yielding 150 (2 × 75) base pairs from the final library fragments. Sequencing reads were 
analyzed and aligned to human genome hg18 with the Eland algorithm in CASAVA 1.6 
software (Illumina), as has previously been described9–11. A mismatched base was identified 
as a mutation only when (i) it was identified by more than five distinct reads; (ii) the number 
of distinct reads containing a particular mismatched base was at least 10% of the total 
distinct reads; and (iii) it was not present in >0.5% of the reads in the matched normal 
sample. “Distinct reads” were defined as reads that had different sequences at either the 5′ or 
3′ end of the sequenced fragment, thereby indicating that they originated from different 
template molecules. From our previous studies using these quality criteria, more than 90% 
of mutations are confirmed as true somatic mutations using independent platforms. SNP 
search databases included the NCBI’s database (http://www.ncbi.nlm.nih.gov/projects/
SNP/).
Purification of mRNA and synthesis of cDNA
JHU—From 5 tumors with available RNA, 10ug total RNA were purified with Dynal 
Oligo(dT) beads twice following suggested protocol. Briefly, 50ul Oligo(dT) beads(cat# 
61002, Invitrogen) were washed with 250ul L/B buffer. Total RNA were mixed to 500ul 
L/B buffer and added to the isolated beads. The mixture was rocked in room temperature for 
15 minutes. The beads were isolated and washed with 2X wash buffer A and 1X wash buffer 
B. Then the beads were resuspended in 25ul DEPC water and incubated in 85 °C for 2 
minutes. Place the tube on the magnet for 1 min, then immediately collect the supernatant. 
The supernatant was purified one more time and collected in 13ul DEPC water. 12ul of 
Oligo(dT) selected mRNA was mixed with 2ul 50ng/ul (N)6 random primers and used to 
synthesize double strand cDNA with the SuperScript Double-Stranded cDNA Synthesis 
Kit(cat#11917-010, Invitrogen). The cDNA reaction mixture was cleaned with Qiagen PCR 
purification kit and eluted in 100ul Elution buffer.
UCSF and OSU—RNA was extracted from fresh frozen tissue samples by 
homogenization, guanidine thiocyanate lysis and column purification using the ZR Viral 
RNA Kit (Zymo Research) in a laminar flow cabinet. RNA was then treated with DNAse-1 
(New England Biolabs) before being subject to rRNA depletion with Terminator™ 5′-
Phosphate-Dependent Exonuclease (Illumina) according to manufacturer instructions.
Complementary DNA (cDNA) was subsequently prepared using a random-hexamer PCR 
amplification method. Reverse transcription was carried out by mixing 100ng RNA with 
1000pmol of random hexameric primer in a total volume of 6μl, heating to 65°C for 5 min 
and then cooling to 4°C. One μL of 12.5 mM dNTPs, 2 μL of 5X RT buffer, 0.5 μL 0.1 M 
DTT and 0.5 μL of Superscript III® reverse transcriptase (Life Technologies) were then 
added and the reaction was incubated at 42°C for 60 min, then 94°C for 4 min. To this, 7.5 
μL ddH2O, 2.25 μL RT buffer (Life Technologies) and 0.25 μL RNAseH/RNAseA were 
added and the reaction was incubated at 37°C for 15 min, then at 94°C for 2 min. One μL of 
RT buffer, 0.5 μL Klenow fragment exonuclease (New England Biolabs), 1 μL of 12.5 mM 
dNTPs and 2.5 μL H2O were then combined and the reaction was incubated at 37°C for 15 
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minutes. DNA was extracted from this reaction by spin-column purification (DNA Clean & 
Concentrator-5, Zymo Research Inc.) using 75 μL of binding buffer and eluting in 10 μL 
H2O. Metagenomic sequencing libraries were constructed using Nextera sample preparation 
kits with 20ng input DNA according to manufacturer’s instructions (Illumina). Individual 
samples were then pooled in a 1.5 mL microfuge tube containing 10 μl of 0.5 M EDTA. The 
ZR DNA Clean-Up Kit (Zymo Research) was employed to purify the DNA, which was 
subsequently eluted in 20 μl ddH2O. Size selection for fragments 500–600 bp in length was 
performed on 10 μl of this sample using the LabChip XT DNA system (Perkin Elmer). This 
was followed by a 20-cycle PCR amplification using the KAPA Real-Time Library 
Amplification Kit (Kapa Biosystems) according to manufacturer instructions, and followed 
by a final DNA purification using the ZR DNA Clean-Up Kit (Zymo Research). Fifteen nM 
of DNA was then utilized for sequencing on an Illumina HiSeq 2500instrument as 
previously described 12–16.
Transcriptome Analysis for Viral Pathogen Discovery
First, raw Illumina sequences consisting of 75 bp paired-end reads were quality filtered to 
exclude low-complexity, homopolymeric, low-quality sequences and Illumina adapter 
sequences as described previously 12–16. Filtered sequences were then iteratively aligned 
against the NCBI NT database utilizing Bowtie2, The Basic Local Alignment Search Tool 
(BLAST) and Blast-Like Alignment Tool (BLAT) algorithms to subtract reads originating 
from human, bacteriophage and bacterial genomes 12–17. The remaining sequences were 
then BLAST aligned against the NCBI viral genome database as described previously 12–17. 
De novo assembly of the remaining unaligned reads was attempted using the Trinity 
algorithm followed by BLASTX alignment of contigs to the NCBI viral genome database 18. 
Second, an independent viral detection procedure was also performed, consisting of 
MapSplice alignment of reads to a database of human genome and virus genome sequence 
and quantification of viral expression presence 19, 20. Third, the PathSeq algorithm was used 
to perform computational subtraction of human reads, followed by alignment of residual 
reads aligned to microbial reference genomes including bacterial, viral, archaeal, and fungal 
sequences (downloaded from NCBI in June, 2012). These alignments result in the 
identification of reads mapping with viral genomes in RNA sequencing of oral tongue 
squamous cell cancer samples. Human reads were subtracted by first mapping reads to a 
database of human database sequences using BWA (Release 0.6.1, default settings), 
Megablast (Release 2.2.25, cut-off E-value 10−7, word size 16) and Blastn (Release 2.2.25, 
cut-off E-value 10−7, word size 7, nucleotide match reward 1, nucleotide mismatch −3, gap 
open cost 5, gap extension cost 2) 21–23. Human sequence databases used for the subtraction 
were the Ensembl human cDNA database followed by human genome and transcriptome 
database (downloaded from Ensembl and NCBI in November 2011). Only sequences with 
perfect or near perfect matches to the human genome were removed in the subtraction 
process. In addition, low complexity and highly repetitive reads were removed using Repeat 
Masker (version open-3.3.0, libraries dated 2011-04-19)24. To identify microbial reads, the 
resultant potential non-human reads were aligned with Megablast (Release 2.2.25, cut-off E-
value 10−8, word size 16) to a database of microbial and human reference genomes. Then, 
the unclassified reads were used to identify presence of new or novel viruses through de 
novo assembly of reads using Trinity (Release 03122011)18.
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Contigs assembled from the Trinity assembler were aligned to human genome plus 
microbial databases using Blastn (Release 2.2.25, word size 7, nucleotide match reward 1, 
nucleotide mismatch −3, gap open cost 5, gap extension cost 2) and aligned to NR database 
(downloaded from NCBI in May 2011) using Blastx (Release 2.2.25, word size 3, nucleotide 
match reward 1, nucleotide mismatch −3, gap open cost 11, gap extension cost 1) to identify 
the new or novel viral species in the dataset. Then, the contigs (that are >=500 bases) that 
showed weak or good homology to viruses were manually reviewed using online Blastx 
algorithm (with default settings) from NCBI against the NR database available at NCBI 
homepage. (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Sanger Sequencing of p53 cDNA
All samples that underwent transcriptomic analysis from UCSF and Ohio State were also 
subjected to Sanger Sequencing of exons 4–10 of p53 cDNA. Exons were first amplified by 
PCR and then sequenced using primers and run conditions listed in Supplemental Index 
Section 2. Samples were sequenced on a 3730xl DNA Analyzer (Applied Biosystems) and 
resulting data was analyzed with Sequencher (GeneCodes) to genotype for variations.
Statistical Analysis
Descriptive statistics were used to summarize the clinicopathologic characteristics of our 
cohort of oral tongue SCC patients. Comparative statistics were used to describe differences 
between the never-smokers and smokers groups with respect to clinicopathologic 
parameters. The Fisher’s exact test was used with statistical significance designated by P < 
0.05. Comparison of never-smokers and smokers with respect to exomic sequencing results 
was also performed using Fisher’s exact test for categorical variables, and Student’s t-test 
for continuous variables, again with statistical significance designated by P < 0.05.
Results
Comparison of clinical and demographic characteristics
Clinicopathologic data were analyzed for 94 patients treated for oral tongue SCC. Of the 94 
oral tongue cancer patients, 89 had sufficient tobacco usage data for analysis (Table 1). The 
non-smokers were significantly younger on average (50.4 years of age) when compared to 
smokers (61.9 years of age, P=0.003). Non-smokers appeared more likely to be female than 
smokers, although this did not reach statistical significance (58.5% female vs. 38.9%, 
respectively; P=0.069). The patients within this study were predominantly white (79 of 94). 
Therefore we could not make meaningful comparisons regarding racial differences. There 
were no differences in pathological TNM classification or treatment regimen employed. 
However, the non-smokers appeared to have poorer tumor differentiation on histopathology 
(86.4% vs. 67.7% moderate to poorly differentiated respectively, P=0.053), and a higher rate 
of tumor recurrence (43.1% vs. 20.0% respectively, P=0.026), after a mean follow up 
interval of 52 months (range 1 month to 27 years).
Exomic Sequencing Data
Table 2 summarizes the results of 6 lateral tongue tumors analyzed by next-generation 
exomic sequencing. Five lateral tongue tumors from smokers were selected as controls from 
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previously sequenced cases 20. Other than smoking status, there were no other differences in 
clinical characteristics between non-smokers that underwent exomic sequencing and the 
historical smoker controls. All of the tumors from non-smokers were tested for the presence 
of HPV and EBV, and these viruses were not detectable.
In the non-smoker tumors, the average distinct coverage of each base in the targeted region 
was 116-fold and 92.5% of targeted bases were represented by at least ten reads. In the 
previously sequenced tumors from smokers, the average distinct coverage of each base in 
the targeted region was 77-fold and 91.5% of targeted bases were represented by at least 10 
reads. After applying the same stringent quality filtering (see Materials and Methods) and 
visual inspection of both groups of tumors, the sequencing results of the cancers from the 6 
non-smokers revealed 510 high confidence somatic mutations in 482 genes (Table S1). 
Using the same criteria, we identified 342 high confidence somatic mutations in 324 genes 
in the 5 cancers from smokers.
The tumors from nonsmokers contained an average of 84.8 ± 71.7 high confidence 
mutations (range 10–193). The tumors from smokers contained an average of 68.4 ± 32.4 
high confidence mutations (range 18–113). The mean number of mutations was not 
statistically different between cancers from smokers and cancers from non-smokers (P=0.65, 
Student’s t-test).
The recurrently mutated genes or genes in a common pathway in our cohort of cancers from 
non-smokers were CTNNA3, EIF3A, EP300, FXR1, NEK8, NOTCH1 (NOTCH2 and 
NOTCH3 in individual tumors), PIK3CA, PKHD1L1, PTCHD2, RALGAPB, SPEN, and 
UBR4. In the cancers from smokers, the recurrent mutations were in CD101, LAMA1, 
NCAPD3, RIMBP2, SI, SYNE, and TP53. All 5 tumors from smokers had TP53 mutations (5 
of 5), whereas only one cancer from a non-smoker had a TP53 mutation (1 of 6, P=0.02, 
Fisher’s exact test).
The difference in frequency of NOTCH gene family mutations between non-smokers (3 of 6 
tumors) and smokers (zero tumors) was not significant. In a previous study, we also detected 
telomerase reverse transcriptase (TERT) promoter mutations in 5 of 11 (45%) tumors 
sequenced 25. There was no difference in frequency of TERT mutations between non-
smokers (3 of 6 tumors) and smokers (2 of 6).
The mutational spectrum for the two groups was significantly different although the most 
common substitution in cancers from both non-smokers and smokers was C:G>T:A (Table 
3). Compared to cancers from non-smokers, a greater proportion of mutations in cancers 
from smokers were either A:T>G:C (P<0.0001) or A:T>T:A substitutions (P<0.0001). 
Conversely—compared to cancers from smokers, a greater proportion of mutations in 
cancers from non-smokers were C:G>G:C transversions (P<0.0001).
Viral Discovery
Three separate transcriptomic analyses were undertaken to search for the presence of 
potentially causative viral pathogens. First, RNA from fifteen tumors from non-smoking 
patients, five tumors from smoking patients, one healthy tongue sample (negative control) 
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and one HPV positive oropharyngeal tumor (positive control) from UCSF, OSU and JHU 
was analyzed through an established iterative approach. The patients for this portion of the 
study were young, with an average age of 40 years (38 years for smoking patients and 41 for 
non-smoking patients). 45% were female (40% for smoking patient and 46% for non-
smoking patients) and 75% were Caucasian.
Raw Illumina sequences ranged in number from 4 – 63 × 106 (average 18 × 106) reads per 
tissue sample. To search for the presence of non-host derived sequences, we removed human 
derived sequences through iterative alignment using Bowtie2 and BLAT alignments to the 
human genome (hg19) followed by low complexity filtering. This resulted in an average of 
0.16% (range 0.01%–0.44%) of initial reads. Of these, an average of 0.0017% (range 
0.0001%–0.0116%) of reads aligned to the viral database. As expected, the HPV 16 positive 
oropharyngeal sample, used as a positive control, demonstrated the greatest number of 
aligned viral reads with 0.00025% (n=14) mapping to HPV 16. This compares to 0.018% of 
reads that aligned to HPV-16 in a recent report that evaluated HPV 16-positive cervical 
squamous cell carcinoma 26. None of the sample libraries contained a higher percentage of 
total viral-matching reads than the HPV-derived read count from the HPV-positive control 
sample. One of the non-smoking samples contained 0.00016% of reads (n=6) that aligned to 
HHV-1 (Table S4). All other hits were below meaningful levels. Remaining unaligned reads 
assembled utilizing the Trinity algorithm did not show any additional alignments to the viral 
genome database 18.
JHU samples were then analyzed with MapSplice19, which did not reveal any meaningful 
viral reads. Lastly, JHU samples were again analyzed using PathSeq and Trinity for denovo 
assembly from unclassifiable sequences (See Supplementary Index Section 3, Methods and 
Tables S5 and S6 for detailed analysis). Two samples showed the presence of low levels (12 
– 25 reads) of human herpes virus 4 (HHV4) (Table S7). No additional alignments to the 
viral genome database were found. In summary, three independent search algorithms 
identified no potentially causative viruses. No HPV was found in any of the tumors other 
than the HPV positive control.
TP53—All samples that underwent transcriptomic analysis from UCSF and Ohio State 
underwent Sanger Sequencing of exons 4–10 of TP53 cDNA. In concordance with the 
exome sequencing data, 1 of 10 (10%) of the cancers from non-smoking patients had a 
deleterious TP53 mutation while 2 out of 5 (40%) of the cancers from patients who smoked 
had deleterious TP53 mutations (Table S3).
Discussion
This examination of oral tongue cancer patients stratified by smoking status revealed distinct 
clinico-demographic and biological differences between these groups. Compared to 
smokers, the non-smokers with oral tongue SCC were more likely to be less than 50 years of 
age, and there was a trend towards a higher proportion of non-smokers being female. While 
our cohort was small, there was also a suggestion that non-smokers with oral tongue SCC 
may have more poorly differentiated carcinomas, and a higher rate of recurrence after 
primary treatment. Non-smokers, however, did not exhibit more advanced tumor staging at 
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time of diagnosis. Next-generation exomic sequencing and Sanger Sequencing data suggest 
that cancers from non-smokers have a lower prevalence of TP53 mutations. This preliminary 
evidence suggests a biological difference in the development of oral tongue SCC in these 
two groups.
In contrast to an overall declining incidence of HNSCC, due in part to reduced tobacco 
consumption worldwide, several subsites of HNSCC have experienced an increase in 
incidence 27. The identification of high-risk HPV-associated oropharyngeal cancers as a 
distinct subgroup has led to recognition of HNSCC as a biologically heterogeneous 
disease 5, 28. The oral tongue subsite likewise appears to have a rising incidence in young 
patients, most evident in white females, based on the Surveillance, Epidemiology, and End 
Results (SEER) database 4, 29.
More recently we reported an analysis of the Nationwide Inpatient Sample (NIS) all-payer 
database, comparing the demographic characteristics of 15,083 oral tongue cancer patients 
to 29,268 patients with oral cavity cancer from other subsites 30, 31. In multivariate 
regression analysis, oral tongue cancer patients were more likely to be younger than 40 years 
of age, white, and female. Although we did not compare our oral tongue SCC cohort to other 
oral cancer subsites, we have found that the subgroup of non-smokers is similarly younger 
and more likely to be female than smokers 31, 32. Whether the rising incidence of oral tongue 
SCC reported in SEER analysis is primarily occurring in non-smokers is unclear since the 
SEER database does not report tobacco consumption. In our study, non-smokers comprised 
over half of our oral tongue SCC cohort, making this subgroup a significant proportion of 
patients and provoking scientific investigation into biological differences between these two 
exposure subgroups. Furthermore, there is a unique clinical pattern to oral tongue cancer in 
nonsmokers. Virtually all cases arise on the lateral border of the tongue and on one side 
only. All cases of recurrence/second tongue cancer in our series to date have occurred on the 
same side as the incident cases, often, although not always preceded by a prolonged period 
of “smoldering” erythroleukoplakia (showing a fluctuating degree of severity and biopsy 
evidence of fluctuating degree of epithelial dysplasia). In contrast, oral cavity cancers in 
smokers occur more commonly on the floor of mouth, and second primary cancers may 
appear anywhere within the upper aerodigestive tract mucosa.
Given these clinico-demographic differences, we were interested in determining the 
molecular profiles of oral tongue SCC from non-smokers and smokers. The most striking 
differences in mutation patterns between cancers from non-smokers and smokers were seen 
in the prevalence of TP53 mutations. Both Agrawal et al and Stransky et al have 
independently reported TP53 as the most frequently mutated genes on exomic sequencing of 
all sites of HNSCC. The majority of tumors reported by Agrawal et al and Stransky et al 
harbored TP53 mutations or TP53 inactivation through HPV 33, 34. In our study only 2 of 16 
cancers from non-smokers had a TP53 mutation, whereas 7 of 10 cancers from smokers had 
TP53 mutations. Given that the vast majority of HNSCC have inactivation of TP53 either 
through somatic mutation or HPV E6, it is possible that TP53 inactivation occurs via a 
mechanism other than somatic mutation in non-smokers. Alternatively, a TP53 independent 
pathway may drive oncogenesis in non-smokers that is not currently understood. Larger 
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cohorts of oral tongue SCC tumors need to be studied in patients with accurate tobacco use 
to validate the results of this genomic sequencing analysis.
The young age of the patients, lack of carcinogen exposure and lack of TP53 mutations 
raises the possibility that a known or novel virus could be driving tumor development. 
Considerable interest has circulated around this topic as a possible explanation for the 
increasing incidence of oral tongue SCC in non-smokers. We were unable to identify any 
potentially causative viruses, including HPV, in 19 tongue tumor samples through 
transcriptomic analysis with three separate approaches. Although our current analysis does 
not support the role of an infectious agent in these cases, it is important to note that this 
work does not definitively rule out the involvement of such an agent. The concept of “hit 
and run” viral transformation could account for a viral role in oncogenesis without 
persistence of viral genomic DNA within cancer cells 33, 34. The hit and run hypothesis 
suggests that oncogenic viruses can either integrate into the host cell genome or remain 
episomal at a particular point in the progression to cancer. The viral genome may be 
subsequently lost and become undetectable by the time of clinical diagnosis. Experimental 
evidence for such a mechanism has been sought in certain Hodgkin’s lymphoma 
subtypes 35, 36, 37 and nasopharyngeal carcinoma 38, 39, 40, while the clinical relevance 
remains unknown. Future directions may utilize methods to detect epigenetic signatures of 
previous viral infection at a point when viral DNA has been lost from cancer cells.
Two landmark studies independently demonstrated that non-smokers with HNSCC harbored 
fewer mutations compared to smokers 33, 3441,42. We did not observe a statistically 
significant difference between the number of somatic mutations in cancers from non-
smokers and smokers. However, our study may not have had sufficient power to detect 
differences in overall mutation rates between cancers from smokers and non-smokers. 
Nevertheless, we did identify other evidence of tumor heterogeneity based on tobacco 
exposure. Surprisingly, the mutational spectrum in cancers from smokers was not enriched 
in the C:G>A:T transversions that are typically associated with smoking3543. Cancers from 
smokers demonstrated more A:T>T:A and A:T>G:C transitions, whereas cancers from non-
smokers showed higher rates of C:G>G:C transversions. Various oxidative stresses induce 
C:G>G:C transversions suggesting oxidative DNA damage in non-smokers may be coming 
from an unique, yet unidentified, source 36, 3744, 45.
This is the first study to examine the genomic and metagenomic profiles of oral tongue SCC 
in non-smoking patients compared to smoking patients. There are several limitations to this 
study. We acknowledge the relatively small size of samples undergoing exome sequencing 
as a limitation. This study did not investigate the role of other genomic alterations including 
chromosomal rearrangements and copy number variations in oral tongue SCC, nor did we 
characterize the potential epigenetic changes that may contribute to oncogenesis in this 
tumor type. At present time no large studies exist that compare long-term prognosis between 
smokers and non-smokers with oral tongue SCC and our study was not designed for robust 
survival analysis. While non-smokers had a higher rate of tumor recurrence, we recognize 
the limitation of small sample size in concluding that non-smokers with oral tongue SCC 
have more aggressive tumors. Given the significant and novel clinical and genetic 
differences, we feel that it is important to report this early, but significant data to draw 
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attention to an emerging clinical entity. Further epidemiologic, microbiologic and molecular 
study of lateral tongue cancers is necessary.
Conclusion
This study provides preliminary evidence that oral tongue SCC patients represent a 
heterogeneous group with unique biologic and clinical characteristics. Although there are 
genetic differences in the young non-smokers, given the limited samples size, there may 
exist other unidentified drivers of carcinogenesis. Acquiring larger cohorts for molecular 
studies will strengthen the evidence for differing tumor biology, and facilitate the search for 
unidentified causal factors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 3
Spectra of all mutations
Nonsmokers Smokers
Mutations Number Percent (%) Number Percent (%)
A:T>C:G 19 3.7 15 4.4
A:T>G:C 34 6.7 52 15.2
A:T>T:A 15 2.9 35 10.2
C:G>A:T 47 9.2 44 12.9
C:G>G:C 174 34.1 52 15.2
C:G>T:A 213 41.8 133 38.9
Indel 8 1.6 11 3.2
Total 510 100.0 342 100.0
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